Nyxoah Takes Center Stage at Healthcare Conference
Nyxoah SA, a cutting-edge medical technology company, is set to make waves at the upcoming Piper Sandler 37th Annual Healthcare Conference. Known for its pioneering work in the treatment of Obstructive Sleep Apnea (OSA) through innovative neuromodulation techniques, the company aims to highlight its breakthrough solutions.
The Fireside Chat Schedule
Management from Nyxoah plans to participate in an insightful fireside chat on a future date. This engaging session is expected to provide valuable insights into the company’s latest achievements and future direction, scheduled for December at 1:30 p.m. ET. The discussion will be accessible via a live audio webcast, ensuring that all interested stakeholders can be part of the engagement.
Nyxoah's Game-Changing Technology
At the heart of Nyxoah’s mission is the development of its Genio system, which is a leadless, battery-free hypoglossal neurostimulation therapy for OSA. This innovative approach represents a significant leap forward for patients suffering from a condition that affects many individuals globally, often leading to severe health complications.
Achievements and Milestones
Since gaining its CE Mark approval in 2019 following positive results from the BLAST OSA study, Nyxoah has undertaken impactful ventures to reach a broader patient demographic. The completion of successful IPOs on Euronext Brussels and NASDAQ has further solidified its position in the market. Recently, after favorable outcomes from the BETTER SLEEP study, the company expanded its therapeutic indications, making treatments available to patients previously deemed unsuitable for existing therapies.
The Future of Sleep Apnea Treatment
With the recent FDA approval for select adult patients with moderate to severe OSA, the Genio system is poised to provide relief to many who struggle with this debilitating condition. Nyxoah continues to push boundaries in medical technology, driven by their belief that everyone deserves a good night’s sleep.
Learn More About Nyxoah
For those interested in further information about Nyxoah and its innovative solutions for sleep apnea, the company invites everyone to explore their official website. They provide a wealth of information on their treatments, ongoing studies, and future initiatives to help patients manage their conditions effectively. Nyxoah remains dedicated to the welfare of OSA patients, enabling them to lead fulfilling lives.
Contact Information
To reach out for further inquiries or details, potential collaborators and investors can contact the team at Nyxoah. Key contacts include John Landry, the Chief Financial Officer, and Rémi Renard, the Chief Investor Relations & Corporate Communication Officer, who are both available for discussions and provide an open channel for engagement.
Frequently Asked Questions
What is Nyxoah?
Nyxoah is a medical technology company focused on developing innovative solutions for treating Obstructive Sleep Apnea through neuromodulation.
When will Nyxoah participate in the Healthcare Conference?
Nyxoah's management team will participate in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference.
How does the Genio system work?
The Genio system is a battery-free, leadless hypoglossal neurostimulation therapy designed specifically for OSA patients, providing a unique treatment option.
What recent approvals has Nyxoah received?
Nyxoah recently received FDA approval to treat a subset of patients with moderate to severe OSA.
How can I learn more about Nyxoah's products?
Visit Nyxoah's official website to discover more about their innovative solutions and ongoing research in sleep apnea treatment.
